S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.37 (+4.94%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.37 (+4.94%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.37 (+4.94%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.37 (+4.94%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BA   179.96 (+2.45%)
Log in

NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

$39.56
+2.15 (+5.75 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$36.11
Now: $39.56
$39.80
50-Day Range
$31.06
MA: $38.03
$45.63
52-Week Range
$18.07
Now: $39.56
$46.50
Volume170,688 shs
Average Volume106,573 shs
Market Capitalization$1.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$1.27 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableNot Optionable

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has increased by 46.5% and is now trading at $38.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for Odonate Therapeutics.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Odonate Therapeutics.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) announced its earnings results on Tuesday, April, 28th. The company reported ($0.99) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.04. View Odonate Therapeutics' earnings history.

What price target have analysts set for ODT?

1 brokerages have issued 1-year target prices for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they expect Odonate Therapeutics' share price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 31.6%. View analysts' price targets for Odonate Therapeutics.

Has Odonate Therapeutics been receiving favorable news coverage?

Media coverage about ODT stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Odonate Therapeutics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Odonate Therapeutics.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $38.00.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $1.22 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.